Intestinal and esophageal microbiota in esophageal cancer development and treatment
Esophageal cancer (EC) is the eleventh most commonly diagnosed cancer, and its prognosis remains poor. Several challenges remain for improving the clinical outcomes of EC, and improving technologies for early detection, diversifying treatment options, and advancing personalized treatment are essenti...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2025.2505118 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849321365886205952 |
|---|---|
| author | Yuta Baba Kohei Tajima Kiyoshi Yoshimura |
| author_facet | Yuta Baba Kohei Tajima Kiyoshi Yoshimura |
| author_sort | Yuta Baba |
| collection | DOAJ |
| description | Esophageal cancer (EC) is the eleventh most commonly diagnosed cancer, and its prognosis remains poor. Several challenges remain for improving the clinical outcomes of EC, and improving technologies for early detection, diversifying treatment options, and advancing personalized treatment are essential. Alterations in the intestinal and esophageal microbiota are associated with the pathogenesis and progression of EC; for instance, Fusobacterium nucleatum is important in the pathogenesis and progression of esophageal squamous cell carcinoma. Therefore, a novel diagnostic biomarker may be identified using the intestinal microbiota. Furthermore, targeting the intestinal and esophageal microbiota may help in the early detection of EC, use of a novel prognostic biomarker, and even the detection of a therapeutic target, resulting in a more individualized therapeutic approach for EC. In this review, we summarize the clinical research focused on the intestinal and esophageal microbiota in EC development and its treatment, and discuss the challenges in the clinical application of intestinal and esophageal microbiota. |
| format | Article |
| id | doaj-art-bb4b83f381b1453eb54e3d6b35bef7af |
| institution | Kabale University |
| issn | 1949-0976 1949-0984 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj-art-bb4b83f381b1453eb54e3d6b35bef7af2025-08-20T03:49:46ZengTaylor & Francis GroupGut Microbes1949-09761949-09842025-12-0117110.1080/19490976.2025.2505118Intestinal and esophageal microbiota in esophageal cancer development and treatmentYuta Baba0Kohei Tajima1Kiyoshi Yoshimura2Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, JapanDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, JapanDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, JapanEsophageal cancer (EC) is the eleventh most commonly diagnosed cancer, and its prognosis remains poor. Several challenges remain for improving the clinical outcomes of EC, and improving technologies for early detection, diversifying treatment options, and advancing personalized treatment are essential. Alterations in the intestinal and esophageal microbiota are associated with the pathogenesis and progression of EC; for instance, Fusobacterium nucleatum is important in the pathogenesis and progression of esophageal squamous cell carcinoma. Therefore, a novel diagnostic biomarker may be identified using the intestinal microbiota. Furthermore, targeting the intestinal and esophageal microbiota may help in the early detection of EC, use of a novel prognostic biomarker, and even the detection of a therapeutic target, resulting in a more individualized therapeutic approach for EC. In this review, we summarize the clinical research focused on the intestinal and esophageal microbiota in EC development and its treatment, and discuss the challenges in the clinical application of intestinal and esophageal microbiota.https://www.tandfonline.com/doi/10.1080/19490976.2025.2505118Gut microbiotaintestinal microbiotaesophageal microbiotaesophageal canceresophageal adenocarcinomaesophageal squamous cell carcinoma |
| spellingShingle | Yuta Baba Kohei Tajima Kiyoshi Yoshimura Intestinal and esophageal microbiota in esophageal cancer development and treatment Gut Microbes Gut microbiota intestinal microbiota esophageal microbiota esophageal cancer esophageal adenocarcinoma esophageal squamous cell carcinoma |
| title | Intestinal and esophageal microbiota in esophageal cancer development and treatment |
| title_full | Intestinal and esophageal microbiota in esophageal cancer development and treatment |
| title_fullStr | Intestinal and esophageal microbiota in esophageal cancer development and treatment |
| title_full_unstemmed | Intestinal and esophageal microbiota in esophageal cancer development and treatment |
| title_short | Intestinal and esophageal microbiota in esophageal cancer development and treatment |
| title_sort | intestinal and esophageal microbiota in esophageal cancer development and treatment |
| topic | Gut microbiota intestinal microbiota esophageal microbiota esophageal cancer esophageal adenocarcinoma esophageal squamous cell carcinoma |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2025.2505118 |
| work_keys_str_mv | AT yutababa intestinalandesophagealmicrobiotainesophagealcancerdevelopmentandtreatment AT koheitajima intestinalandesophagealmicrobiotainesophagealcancerdevelopmentandtreatment AT kiyoshiyoshimura intestinalandesophagealmicrobiotainesophagealcancerdevelopmentandtreatment |